Symposium

Cancer Genomics and Tumor Immunotherapy Symposium: A Clinical Perspective

November 17, 2017

The Cancer Genomics and Tumor Immunotherapy Symposium: A Clinical Perspective is a key educational event, jointly hosted by the Cancer Genomics Program and the Tumor Immunotherapy Program at the Princess Margaret Cancer Centre. This one-day symposium will include focused talks and panel discussions on cancer genomics and tumor immunotherapy. International, national, and local speakers will share with participants emerging therapies and technologies, novel genomic approaches for diagnosis, the clinical development of tumor-derived DNA as a biomarker for cancer, immunogenomic-based drug development, response, and resistant mechanisms to immune checkpoint therapy, and precision oncology for young people.

The target audience for this meeting includes academic and community oncologists, pharmaceutical leaders, regulatory agencies, basic and translational scientists and trainees. This symposium will provide a clinical and translational perspective on genomics and immunotherapy as it applies to precision cancer medicine at the point of care.


This one-day symposium will be held at the MaRS Discovery District in downtown Toronto:

Date: Friday, November 17, 2017
Location:
MaRS Discovery District
101 College Street,
Toronto, ON
M5G 1L7

SPEAKERS
KEYNOTE:
Dr. Max Diehn, MD, PhD (Stanford University)


CONFIRMED SPEAKERS:

  • Meredith Irwin, MD (Hospital for Sick Children)
  • Philippe Bedard, MD (Princess Margaret Cancer Centre)
  • Trevor Pugh, PhD (Princess Margaret Cancer Centre)
  • Adrian Sacher, MD (Herbert Irvine Comprehensive Cancer Center)
  • Morag Park, PhD (McGill University)
  • Frederick Locke, MD (Moffitt Cancer Center)
  • Pamela L. Schwartzberg, MD, PhD (National Human Genome Research Institute)


SESSION CO-CHAIRS:

  • Lillian Siu, MD (Princess Margaret Cancer Centre)
  • Pam Ohashi, PhD (Princess Margaret Cancer Centre)


Topics to be discussed in a presentation or panel include:

  • Clinical Applications of High Throughput Sequencing-Based Circulating Tumor DNA Analysis
  • Precision Oncology for Young People
  • Update on the Cancer Genomics Program at Princess Margaret
  • The Impact of Tumor Microenvironment on Immune Response in Triple Negative Breast Cancer
  • Response and Resistance Mechanisms to Immune Checkpoint Therapy
  • Immunogenomics as a Tool to Guide Rational Drug Development and Clinical Care
  • CAR T Therapy
  • Mechanisms of T Cell Exhaustion

  • FULL AGENDA & MEETING REGISTRATION:
    Please visit our website to view the full symposium agenda and to register for this important event:
    http://www.pm-genomics-io-symposium.ca


    Contact Us
    For more information regarding our program feel free to connect with us:
    cgp@uhn.ca
    (416)946-2993


    Applied Cancer Genomics Symposium

    October 3rd 2014

    The inaugural Applied Cancer Genomics Symposium was held on Friday, October 3rd, 2014 at the MaRS Discovery District to great success. It featured Canadian and international speakers presenting on four main topics: genomic sequencing in cancer, informatics, clinical applications of genomics and the future direction of precision medicine. Participants came from a variety of backgrounds, including healthcare (oncologists, pathologists, laboratory technicians), research, industry and members of the Princess Margaret Cancer Foundation. It was a well-attended inter-professional conference with 200 attendees, which brought together those interested in clinical genomics applications in oncology. One third of the registrants represented trainees, who attended the one-day event to learn more about the rapidly evolving genomic profiling technologies. Healthcare professionals felt the symposium was relevant to their disciplines, and that the talks provided a comprehensive perspective on the future of oncology research. The success of this event was made possible by the numerous sponsors, including The Princess Margaret Cancer Foundation. Click on any image to see a larger view.